Skip to main content

Advertisement

SpringerLink
Log in

Central nervous system toxicity from cancer treatment

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Neurologic complications of cancer therapy are an increasingly important concern in patient management. Improvements in systemic therapies and increasing use of local treatments to target such specific tumor sites as brain or leptomeningeal metastases have resulted in increased incidence of treatment toxicity in the central nervous system (CNS). Recognition of specific treatment-related toxicities, and more importantly, differentiation of treatment toxicity from reversible causes of neurologic dysfunction, are critical. This article reviews the evaluation and treatment of major CNS toxicities related to cancer treatment and conditions that present with similar signs and symptoms. The three most common of these, alterations in cognition and consciousness, seizures, and cerebellar dysfunction, are discussed. Prompt recognition of these problems and their causes will have an impact on patient care in all areas of oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Cohen MZ, Armstrong TS: Cognitive dysfunction. In Cancer Symptom Management, edn 3. Edited by Yarbro CH, Frogge MH, Goodman M. Sudbury, MA: Jones and Bartlett; 2003:635–647.

    Google Scholar 

  2. Tuma R, DeAngelis LM: Altered mental status in patients with cancer. Arch Neurol 2000, 57:1727–1731.

    Article  PubMed  CAS  Google Scholar 

  3. Breitbart W, Strout D: Delirium in the terminally ill. Clin Geriatr Med 2000, 16:357–372.

    Article  PubMed  CAS  Google Scholar 

  4. Casarett DJ, Inouye SK: Diagnosis and management of delirium near the end of life. Ann Intern Med 2001, 135:32–40.

    PubMed  CAS  Google Scholar 

  5. Lawlor PG, Gagnon B, Mancini IL, et al.: Occurrence, causes, and outcome of delirium in patients with advanced cancer. Arch Intern Med 2000, 160:786–794.

    Article  PubMed  CAS  Google Scholar 

  6. Siegal T: Toxicity of treatment for neoplastic meningitis. Curr Oncol Rep 2003, 5:41–49.

    Article  PubMed  Google Scholar 

  7. Bird, T: Memory loss and dementia. In Harrison’s On-Line, New York: McGraw Hill; 2001. http://www.harrisonsonline.com

    Google Scholar 

  8. Wieneke MH, Dienst ER: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995, 4:61–66.

    Article  Google Scholar 

  9. Cimprich B, Ronis DL: Attention and symptom distress in women with and without breast cancer. Nurs Res 2001, 50:86–94.

    Article  PubMed  CAS  Google Scholar 

  10. Cull A, Stewart M, Altman DG: Assessment of and intervention for psychosocial problems in routine oncology practice. Br J Cancer 1995, 72:229–235.

    PubMed  CAS  Google Scholar 

  11. Vigliani MC, Duyckaerts C, Hauw JJ, et al.: Dementia following treatment of brain tumors with radiotherapy administered alone or in combination with nitrosourea-based chemotherapy: a clinical and pathological study. J Neurooncol 1999, 41:137–149.

    Article  PubMed  CAS  Google Scholar 

  12. Keime-Guibert F, Napolitano M, Delattre JV: Neurological complications of radiotherapy and chemotherapy. J Neurol 1998, 245:695–708. Good general overview of the neurotoxic effects of combination chemotherapy and radiotherapy.

    Article  PubMed  CAS  Google Scholar 

  13. Faithful S: Patients’ experience following cranial radiotherapy: a study of the somnolence syndrome. J Adv Nursing 1991, 16:939–946. A seminal article describing the cognitive impact of radiotherapy.

    Article  Google Scholar 

  14. Ahles TA, Saykin AJ, Furstenberg CT, et al.: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20:485–493.

    Article  PubMed  CAS  Google Scholar 

  15. Archibald YM, Lunn D, Ruttan LA, et al.: Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 1994, 80:247–253.

    Article  PubMed  CAS  Google Scholar 

  16. Armstrong C, Mollman J, Corn BW, et al.: Effects of radiation therapy on adult brain behavior: evidence for a rebound phenomenon in a phase I trial. Neurology 1993, 43:1961–1965.

    PubMed  CAS  Google Scholar 

  17. Lilja AM, Portin RI, Hamalainan PI, Salminen EK: Short-term effects of radiotherapy on attention and memory performances in patients with brain tumors. Cancer 2001, 91:2361–2368.

    Article  PubMed  CAS  Google Scholar 

  18. Kiebert GM, Curran D, Aaronson NK, et al.: Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomized phase II trial on dose response (EORTC trial 22844). Eur J Cancer 1998, 34:1902–1909.

    Article  PubMed  CAS  Google Scholar 

  19. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S: Interferonrelated mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990, 26:596–600.

    Article  PubMed  CAS  Google Scholar 

  20. Meyers CA, Obbens EA, Scheibel RS, Moser RP: Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991, 68:88–92.

    Article  PubMed  CAS  Google Scholar 

  21. Valentine AD, Meyers CA, Kling MA, et al.: Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998, 25:39–47.

    PubMed  CAS  Google Scholar 

  22. Capuron L, Ravaud A, Dantzer R: Timing and specificity of the cognitive changes induced by interleukin-2 and interferonalpha treatments in cancer patients. Psychosom Med 2001, 63:376–386.

    PubMed  CAS  Google Scholar 

  23. Ch’ien LT, Aur RJ, Verzosa MS, et al.: Progression of methotrexate-induced leukoencephalopathy in children with leukemia. Med Pediatr Oncol 1981, 9:133–141.

    Article  PubMed  Google Scholar 

  24. Price RA: Histopathology of CNS leukemia and complications of therapy. Am J Pediatr Hematol Oncol 1979, 1:21–30. Classic description of clinical and pathologic aspects of treatmentinduced leukoencephalopathy.

    PubMed  CAS  Google Scholar 

  25. Meadows AT, Evans AE: Effects of chemotherapy on the central nervous system: a study of parenteral methotrexate in longterm survivors of leukemia and lymphoma in childhood. Cancer 1976, 37:1079–1085.

    Article  PubMed  CAS  Google Scholar 

  26. Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981, 65(Suppl 1):89–98. This paper shows the important interactions of radiation and chemotherapy relating to scheduling of treatments. It had a major impact on subsequent therapeutic regimens.

    PubMed  Google Scholar 

  27. Inouye SK: Prevention of delirium in hospitalized older patients: risk factors and targeted intervention strategies. Ann Med 2000, 32:257–263.

    Article  PubMed  CAS  Google Scholar 

  28. Levine PM, Silberfarb PM, Lipowski ZJ: Mental disorders in cancer patients: a study of 100 psychiatric referrals. Cancer 1978, 42:1385–1391.

    Article  PubMed  CAS  Google Scholar 

  29. Silberfarb P: Chemotherapy and cognitive defects in cancer patients. Annu Rev Med 1983, 34:35–46.

    Article  PubMed  CAS  Google Scholar 

  30. Ahles TA, Saykin A: Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 2001, 19:812–820.

    Article  PubMed  CAS  Google Scholar 

  31. Bender CM, Paraska KK, Sereika SM, et al.: Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage 2001, 21:407–424.

    Article  PubMed  CAS  Google Scholar 

  32. Hahn MB, Jassak PF: Nursing management of patients receiving interferon. Semin Oncol Nurs 1988, 4:95–101.

    Article  PubMed  CAS  Google Scholar 

  33. Bender CM: Cognitive dysfunction associated with cancer and cancer therapy. Medsurg Nurs 1995, 4:398–399.

    PubMed  CAS  Google Scholar 

  34. Meyers CA, Scheibel RS: Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology (Huntingt) 1990, 4:115–122.

    CAS  Google Scholar 

  35. Leskinen S, Lapela M, Lindholm P, Minn H: Metabolic imaging by positron emission tomography in oncology. Ann Med 1997, 29:271–274.

    Article  PubMed  CAS  Google Scholar 

  36. Ernst E: The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John’s Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002, 136:42–53. Good review of the use of complementary therapy.

    PubMed  Google Scholar 

  37. Cimprich B: Attentional fatigue following breast cancer surgery. Res Nurs Health 1992, 15:199–207.

    Article  PubMed  CAS  Google Scholar 

  38. Meyers CA, Weitzner MA, Valentine AD, et al.: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998, 16:2522–2527. Initial article supporting the use of stimulants in patients with alternations in cognition related to cancer.

    PubMed  CAS  Google Scholar 

  39. Thompson S, Leigh L, Christensen R, et al.: Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 2001, 19:1802–1808.

    PubMed  CAS  Google Scholar 

  40. Boyle DM: Confusion/delirium. In Clinical Manual for the Oncology Advanced Practice Nurse. Edited by Hawkins RA. Pittsburgh, PA: Oncology Nursing Press; 2000:721–728.

    Google Scholar 

  41. Kuebler KK, Heidrich DE: Delirium/acute confusion. In End of Life Care. Edited by Heidrich DE. Philadelphia: WB Saunders; 2002:253–267.

    Google Scholar 

  42. Meagher DJ: Delirium: optimising management. BMJ 2001, 322:144–149.

    Article  PubMed  CAS  Google Scholar 

  43. Beaumont A, Whittle IR: The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien) 2000, 142:1–15. Summary of the pathogenesis of seizures in patients with brain tumors.

    Article  CAS  Google Scholar 

  44. Goldring S, Rich KM, Picker S: Experience with gliomas in patients presenting with a chronic seizure disorder. Clin Neurosurg 1986, 33:15–42.

    PubMed  CAS  Google Scholar 

  45. Cairncross JG, Posner JB: Neurologic complications of systemic cancer. In Oncologic Emergencies. Edited by Bornstein RD. New York: Grune and Stratton; 1981:73–96.

    Google Scholar 

  46. Szeto HH, Inturrisi CE, Houde R, et al.: Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 1977, 86:738–741.

    PubMed  CAS  Google Scholar 

  47. Gregory RE, Grossman S, Sheidler VR: Grand mal seizures associated with high-dose intravenous morphine infusions: incidence and possible etiology. Pain 1992, 51:255–258.

    Article  PubMed  CAS  Google Scholar 

  48. Armstrong TS, Kanusky J, Gilbert MR: Seize the moment to learn about epilepsy in the person with cancer. Clin J Oncol Nursing 2003, 7:163–169.

    Article  Google Scholar 

  49. Collins RC, Al-Mondhiry H, Chernik NL, Posner JB: Neurologic manifestations of intravascular coagulation in patients with cancer: a clinicopathologic analysis of 12 cases. Neurology 1975, 25:795–806.

    PubMed  CAS  Google Scholar 

  50. Rosen P, Armstrong D: Nonbacterial thrombotic endocarditis in patients with malignant neoplastic diseases. Am J Med 1973, 54:23–29.

    Article  PubMed  CAS  Google Scholar 

  51. Chan KW, Mullen CA, Worth LL, et al.: Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002, 29:963–965.

    Article  PubMed  CAS  Google Scholar 

  52. Leppik IE: Contemporary Diagnosis and Management of the Patient with Epilepsy. Newton, PA: Handbooks in Healthcare; 2000. Provides the standard of care for management of seizures.

    Google Scholar 

  53. Leppik IE, Derivan AT, Homan RW, et al.: Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983, 249:1452–1454.

    Article  PubMed  CAS  Google Scholar 

  54. Dropcho EJ: Paraneoplastic diseases of the nervous system. Curr Treat Options Neurol 1999, 1:417–427. Good summary of neurologic paraneoplastic disorders.

    Article  PubMed  Google Scholar 

  55. Furneaux HM, Rosenblum MK, Dalmau J, et al.: Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990, 322:1844–1851.

    Article  PubMed  CAS  Google Scholar 

  56. Anderson NE, Rosenblum MK, Posner JB: Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol 1988, 24:559–567.

    Article  PubMed  CAS  Google Scholar 

  57. Riehl JL, Brown WJ: Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964, 14:961–967. Early description of chemotherapy-induced neurotoxicity from the initial chemotherapy studies.

    PubMed  CAS  Google Scholar 

  58. Bixenman WW, Nicholls JV, Warwick OH: Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol 1977, 83:789–793.

    PubMed  CAS  Google Scholar 

  59. Moertel CG, Reitemeier RJ, Bolton CF, Shorter RG: Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep 1964, 41:15–18.

    PubMed  CAS  Google Scholar 

  60. Grossman L, Baker MA, Sutton DM, Deck JH: Central nervous system toxicity of high-dose cytosine arabinoside. Med Pediatr Oncol 1983, 11:246–250. Good overview of ara-C-induced neurotoxicity.

    Article  PubMed  CAS  Google Scholar 

  61. Hwang TL, Yung WK, Estey EH, Fields WS: Central nervous system toxicity with high-dose Ara-C. Neurology 1985, 35:1475–1479.

    PubMed  CAS  Google Scholar 

  62. Benger A, Browman GP, Walker IR, Preisler HD: Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a Leukemia Intergroup report. Cancer Treat Rep 1985, 69:240–241.

    PubMed  CAS  Google Scholar 

  63. Moore DH, Fowler WC Jr, Crumpler LS: 5-Fluorouracil neurotoxicity. Gynecol Oncol 1990, 36:152–154.

    Article  PubMed  CAS  Google Scholar 

  64. Winkelman MD, Hines JD: Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 1983, 14:520–527. Important reference confirming loss of Purkinje cells in the cerebellum and the impact of loss on reversibility of ara-C toxicity.

    Article  PubMed  CAS  Google Scholar 

  65. Gottlieb D, Bradstock K, Koutts J, et al.: The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 1987, 60:1439–1441.

    Article  PubMed  CAS  Google Scholar 

  66. Damon LE, Mass R, Linker CA: The association between highdose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 1989, 7:1563–1568.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuro-Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA

    Terri Armstrong MS, APRN, BC & Mark R. Gilbert MD

Authors
  1. Terri Armstrong MS, APRN, BC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark R. Gilbert MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Armstrong, T., Gilbert, M.R. Central nervous system toxicity from cancer treatment. Curr Oncol Rep 6, 11–19 (2004). https://doi.org/10.1007/s11912-996-0004-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-996-0004-x

Keywords

Search

Navigation